NYSE: SBEV
Endovia Health Sciences, Inc.CIK 0001553788 · SIC 2080 · Beverages
Historically, Splash was a portfolio company seeking to manage brands across viable growth segments within the consumer beverage industry. As a result of our lack of capital, we did not generate revenue from February 2025 until March 2026 when we delivered tequila as described below. Our beverage… About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (IREN 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade SBEV commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Splash Beverage Group registers 5M-share secondary offering; company may receive up to $30.8M
8 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Splash Beverage issues 3.8M shares for $608K, diluting existing shareholders by ~16¢/share
2 material changes detected. Sign up free to read the summary.
Splash Beverage discloses NYSE compliance issues, pursuing strategic transactions
3 material changes detected. Sign up free to read the summary.
revenue $4,224, net income -$2.1M. Splash Beverage abandons core business, explores cannabinoid pivot amid 41.5% revenue collapse
5 material changes detected. Sign up free to read the summary.
Latest financial statements
From 10-Q filed Aug 19, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Description | Three months ended June 30 2026 | Three months ended June 30 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Net revenues | — | — | 4,224 | 45,200 |
| Cost of goods sold | — | — | (2,376) | (51,802) |
| Gross profit | — | — | 1,848 | (6,602) |
| Operating expenses: | ||||
| Contracted services | 3,591 | 201,660 | 9,828 | 421,268 |
| Salary and wages | 41,903 | 685,586 | 339,654 | 1,511,682 |
| Non-cash share-based compensation | 1,107,558 | 53,859 | 1,284,530 | 189,568 |
| Other general and administrative | 827,064 | 548,117 | 1,309,649 | 988,511 |
| Sales and marketing | 27,250 | 12,769 | 44,523 | 42,663 |
| Total operating expenses | 2,007,366 | 1,501,991 | 2,988,184 | 3,153,692 |
| Loss from operations | (2,007,366) | (1,501,991) | (2,986,336) | (3,160,294) |
| Other income/(expense): | ||||
| Interest income | 6 | — | 506 | — |
| Interest expense | (231,020) | (625,047) | (1,120,475) | (1,262,392) |
| Other Income/Expense | 244,787 | — | 295,018 | (1,845) |
| Amortization of debt discount | (13,448) | (674,962) | (26,894) | (1,653,683) |
| Gain on Extinguishment of debt | 38,683 | (5,560,482) | 38,683 | (5,560,482) |
| Loss on inventory write off | — | — | (30,078) | — |
| Loss on Asset write off | (11,126) | — | (282,397) | — |
| Loss on Fair Value of investment | (41,554) | — | (41,554) | — |
| Change in FV of derivative | 12,644 | — | 8,664 | — |
| Total other income/(expense) | (1,028) | (6,860,491) | (1,158,527) | (8,478,402) |
| Provision for income taxes | — | — | — | — |
| Net loss from continuing operations, net of tax | (2,008,394) | (8,362,482) | (4,144,863) | (11,638,696) |
| Discontinued operations: | ||||
| Loss from discontinued operations, net of tax | (46,393) | (130,599) | (46,393) | (504,836) |
| Net (loss) from discontinued operations | (46,393) | (130,599) | (46,393) | (504,836) |
| Net loss | (2,054,787) | (8,493,081) | (4,191,256) | (12,143,532) |
| Other Comprehensive Income (Loss) | ||||
| Foreign currency translation loss | 2,178 | 1,168 | (21,111) | (45,902) |
| Total Comprehensive Income (Loss) | (2,052,609) | (8,491,913) | (4,170,145) | (12,189,434) |
| (Loss) per share - continuing operations | ||||
| Basic and diluted | (0.77) | (17.88) | (2.30) | (27.31) |
| (Loss) per share - discontinued operations | ||||
| Basic and diluted | (0.02) | (0.41) | (0.02) | (0.41) |
| Weighted average number of common shares outstanding - continuing operations | ||||
| Basic and diluted | 3,064,905 | 474,969 | 2,126,784 | 446,224 |
Condensed Consolidated Balance Sheets
| Description | June 30, 2026 (unaudited) | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 242,702 | 281,435 |
| Accounts receivable, net | 14,316 | 15,748 |
| Prepaid expenses | 100,307 | 208,051 |
| Inventory | 54,922 | 33,538 |
| Other receivables | 72,149 | 93,221 |
| Deferred finance cost | 416,011 | — |
| Total current assets | 900,407 | 631,993 |
| Non-current assets: | ||
| Deposits | — | 22,734 |
| Investment in Salt Tequila USA, LLC | — | 250,000 |
| Investment in Avicanna, net | 175,925 | — |
| Right of use assets | — | 48,041 |
| Property and equipment | — | 12,926 |
| Total non-current assets | 175,925 | 333,701 |
| Total assets | 1,076,332 | 965,694 |
| Liabilities and Stockholders’ Equity | ||
| Liabilities: | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | 4,091,058 | 4,810,061 |
| Right of use liability, current portion | — | 50,720 |
| Related party notes payable | 389,000 | 389,000 |
| Dividends payable | 1,569,914 | 831,944 |
| Notes payable, net of discounts | 5,997,984 | 6,225,581 |
| Derivative liability | 180,918 | 189,582 |
| Accrued interest payable | 3,076,398 | 2,282,528 |
| Liabilities of discontinued operations | 1,520,105 | 1,480,712 |
| Total current liabilities | 16,825,377 | 16,260,128 |
| Long-term liabilities: | ||
| Notes payable, net of discounts | — | 3,418 |
| Right of use liability net of current portion | — | 2,976 |
| Total long-term liabilities | — | 6,394 |
| Total liabilities | 16,825,377 | 16,266,522 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued | — | — |
| Preferred stock, Series A-1 $0.001 par value, 1,500 shares authorized, 1,300 shares issued and outstanding | 1 | 1 |
| Preferred stock Series B, $0.001 par value, 12% cumulative, 150,000 shares authorized, 87,999 and 122,731 shares issued and outstanding at June 30, 2026 and December 31, 2025 | 87 | 122 |
| Common Stock, $0.001 par, 100,000,000 shares authorized, 4,127,220 shares outstanding at June 30, 2026 and 749,450 shares outstanding at December 31, 2025 | 4,127 | 749 |
| Additional paid in capital | 171,062,303 | 166,563,528 |
| Accumulated other comprehensive income / (loss) | 12,717 | 33,828 |
| Accumulated deficit | (186,828,280) | (181,899,055) |
| Total stockholders’ equity | (15,749,045) | (15,300,828) |
| Total liabilities and stockholders’ equity | 1,076,332 | 965,694 |
Condensed Consolidated Statement of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Net loss | (4,191,256) | (12,143,532) |
| (Income)loss from discontinued operations | 46,393 | (504,836) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 4,642 | |
| Amortization of debt discount | 26,894 | 1,653,683 |
| ROU assets, net | (5,656) | 811 |
| Change in FV of Derivative | (8,664) | — |
| Shares issued for services | — | 35,000 |
| Non-cash share-based compensation | 1,284,530 | 194,621 |
| Loss on write-off of investment | 250,000 | — |
| Loss on fair value of investment | 41,554 | |
| Gain/ (Loss) on extinguishment of debt | — | 5,560,482 |
| Changes in working capital items: | ||
| Accounts receivable, net | 1,432 | 148,119 |
| Inventory, net | (21,384) | 42,072 |
| Prepaid expenses and other current assets | 128,816 | 10,126 |
| Deposits | 22,734 | — |
| Accounts payable and accrued expenses | (382,731) | 2,169,807 |
| Accrued interest payable | 785,166 | 460,164 |
| Net cash used in operating activities continuing operations | (2,022,172) | (1,359,169) |
| Cash flows from investing activities: | ||
| Capital expenditures | 12,926 | — |
| Loss of Disposal/write off | (217,479) | — |
| Net cash used in investing activities continuing operations | (204,553) | — |
| Cash flows from financing activities: | ||
| Proceeds from issuance of Common stock | 2,949,144 | — |
| Proceeds from issuance of debt | — | 1,081,650 |
| Proceeds from issuance of Preferred stock | 651,000 | |
| Principal repayment of debt | (740,041) | (280,484) |
| Net cash provided by financing activities continuing operations | 2,209,103 | 1,452,166 |
| Cash flows from discontinued operations | ||
| Operating cash flows | — | (45,230) |
| Investing cash flows | — | — |
| Financing cash flows | — | — |
| Net cash provided by (used in) discontinued operations | — | (45,230) |
| Net cash effect of exchange rate changes on cash | (21,111) | (45,900) |
| Net change in cash and cash equivalents | (38,733) | 1,867 |
| Cash and cash equivalents, beginning of year | 281,435 | 15,346 |
| Cash and cash equivalents, end of period | 242,702 | 17,213 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for Interest | 71,161 | 132,441 |
| Supplemental disclosure of non-cash investing and financing activities | ||
| Creation of promissory note related to deferred financing costs associated with ELOC proceeds. | 540,132 | — |
| Notes payable and accrued interest converted to common stock (226,770 shares in 2026 & 224,541 shares in 2025) | 84,430 | 1,665,954 |
| Non-cash debt discount in the form of issuance of equity instruments in conjunction with convertible notes | — | 659,958 |
| Series-B Convertible Preferred Stock Issued 126,710 Shares exchanged for $12,670,435 notes payable and accrued interest | — | 16,387,404 |
| Series-C Convertible Preferred Stock Issued 20,000 Shares exchanged for Subscription Receivable | — | 20,000,000 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗
Showing the 30 most recent filings of 48 total.
View all filings for SBEV on SEC EDGARAbout Endovia Health Sciences, Inc.
Source: Item 1 (Business) from the 10-K filed April 15, 2026. Description as filed by the company with the SEC.
Item 1. Business.
Company Overview
Historically, Splash was a portfolio company seeking
to manage brands across viable growth segments within the consumer beverage industry. As a result of our lack of capital, we did not generate
revenue from February 2025 until March 2026 when we delivered tequila as described below. Our beverage operations have historically not
been profitable. Because of our lack of capital to generate revenue, our management reviewed strategic alternatives inside and outside
of the beverage industry. As a result, on March 4, 2026 the Company entered into a non-binding letter of intent setting forth the principal
terms of a potential acquisition of a leading manufacturer and multi-brand operator of federally compliant cannabinoid wellness products.
See “Letter of Intent” immediately below for more information. As of the date of this Report, the Company has not entered
into a definitive written agreement with respect to such potential transaction. The delay has been caused by a quest to make the acquisition
tax-free for the target’s equity holders. Because the process for doing so would delay the closing of the proposed acquisition until
late 2026, the Company has agreed to pay additional cash to the target company’s investors to cover their income taxes and reduce
the equity component of the acquisition.
1
Letter
of Intent
On March 4, 2026, Splash entered into a letter of intent (the
“Letter”) with the target company, Medterra CBD, LLC (“Medterra”), a leading manufacturer and multi-brand operator
of federally compliant cannabinoid wellness products. Pursuant to the Letter, the parties agreed in principal on the terms of a potential
business combination between Medterra and the Company, which transaction is subject to due diligence and execution of a definitive written
agreement and other applicable agreements, receipt of audited financial statements of Medterra and customary closing conditions. In addition,
the Company shall be required to raise capital to pay off Medterra’s debt of approximately $10.4 million. The proposed terms for
the acquisition reflect an enterprise value of Medterra of $37.6 million or the issuance of approximately 54.4 million shares of Common
Stock, which assumes repayment of its outstanding debt and delivery of approximately $10,000,000 in cash to pay off and extinguish the
debt of Medterra and to cover the income taxes of the Medterra equity holders. At closing the Company will issue Medterra investors a
number of shares of the Company’s Common Stock equal to up to 19.99% of the Company’s Common Stock then outstanding, and the
remaining shares will be of two series of convertible preferred stock (“Series X” and “Series X-1”) to be issued
to Medterra’s equity holders based on their existing ownership interests in Medterra. The Series X and X-1 shares will convert at
$0.50 per share. The Common Stock to be issued at the closing shall have full rights equal to all outstanding Common Stock, except the
holders may not vote upon the stockholder approval of the change of control contemplated by the acquisition. The Letter also provides
that the Company will issue Series X-1 to Medterra’s lender with the stated value based upon the equity value of Medterra. In exchange
the lender shall cancel its warrants to purchase equity of Medterra.
Read full description ↓
The Company
now expects it can close the acquisition of Medterra in May 2026. The closing will be subject to the Company’s planned meetings
with investors during the week of April 13th and its ability to raise the necessary capital as well as reaching a definitive
agreement with Medterra and the parties meeting the closing conditions.
Because the Company recently rescinded its June 2025 acquisition of certain water
rights in Costa Rica, it derecognized the $20 million of stockholders’ equity which created a stockholders’ deficit of $15,300,828
at December 31, 2025. The NYSE American Rules required us to have at least $6 million in stockholders’ equity. With the expected
stockholder’s equity created by the Medterra acquisition, the Company will be in compliance with the NYSE American Rules. The Company
is seeking to meet with the NYSE American Staff as soon as possible. There is no assurance that the NYSE American will permit us to maintain
the listing of our Common Stock. See Item 1A – “Risk Factors.”
Our Strategy
Our primary focus is to complete the acquisition of
Medterra as described above under “Letter of Intent.”
In addition, we are focusing on re-commencing material revenue-generating
operations through our beverage business, including through sales of our Chispo Tequila brand subject to obtaining sufficient capital.
In the furtherance of this Chispo tequila opportunity, in December 2025 we purchased $50,000 of inventory for the potential Senior Frogs
order described under “Chispo Tequila” below.
The
Company did not make any sales in the 2025 calendar year after March 2025 due to its lack of capital resources. The
Company estimates that it will initially require $3,000,000 for the Chispo brand as well as general and administrative expenses
for the next 12 months.
Chispo Tequila
Chispo is a tequila brand
which we recently began distributing to one customer. See “Senor Frogs Selection” below. Chispo is an authentic
blue agave blanco tequila, with fresh, sweet citrus, herbal floral notes ideal for cocktail mixing. We have entered into an arrangement
with the Chispo producer under which we agreed to distribute the brand in certain states in the U.S., as well as in Guatemala and Europe.
We expect that we will need approximately $500,000 in new financing to implement this business.
2
Senior Frogs Selection
In January 2026 the Company announced that Senor Frog’s, an internationally
recognized restaurant and entertainment brand known for its vibrant atmosphere and authentic cuisine, selected Chispo Tequila as its house
tequila across an initial group of locations in Florida, the Bahamas, and Mexico. Senor Frog’s belongs to Grupo Anderson’s
Mexico who owns more than 50 business units and 15 distinct restaurant brands across 4 countries. In March 2026, we shipped initial inventory
to a distributor which we expect will permit us to recognize revenue for the three months ended March 31, 2026.
The rollout marks Chispo’s first high-profile
national hospitality partner, providing early validation of the brand’s positioning and quality as it begins to scale in the on-premise
channel. Senor Frog’s selected Chispo following an extensive evaluation of authentic tequila brands, with a focus on taste profile,
consistency, and resonance with its broad and diverse customer base. Chispo’s smooth character and approachable style distinguished
it in a competitive field of premium and value-positioned tequilas. Chispo Tequila is produced in Jalisco, Mexico in partnership with
ZB Distillery, a respected distilling operation known for its commitment to quality and traditional tequila craftsmanship.
Costa Rica Water
On June 25, 2025, the Company entered into an Asset
Purchase Agreement (the “Asset Purchase Agreement”) with a third party (the “Seller”) under which the Seller
sold certain water assets located in Costa Rica to the Company in exchange for $20 million of Series C Convertible Preferred Stock
(the “Series C”). The Company issued the Series C to the Seller. Section 1.04 of the Asset Purchase Agreement required the
Seller to deliver the water assets by December 31, 2025 or pay the Company $20 million in cash. Section 1.04 of the Asset Purchase
Agreement further stated that failure to deliver either the water assets or the $20 million by December 31, 2025 rendered the Series
C to be “null, void, and of no further force or effect.” The Seller failed to comply with either requirement. As a result,
on April 14, 2026, the Board of Directors of the Company terminated the Asset Purchase Agreement and cancelled the Series C effective
December 31, 2025.
3
Competition
We compete with a large variety of other companies
in the marketplace for the sale of alcoholic products. The beverage sector is highly competitive, and include international, national,
regional and local producers and distributors. Competitive factors in the beverage industry include price and promotional activity, advertising
and marketing programs, point-of-sale merchandising, retail space management, customer service, product differentiation, packaging innovations
and distribution methods.
Manufacturing and Co-packing
Although we are responsible for manufacturing tequila
products, we do not directly manufacture these products, but instead outsource such manufacturing to third party bottlers and contract
packers and distillers.
Chispo products are manufactured in Mexico, under
contract manufacturing arrangements. These co-packaging arrangements are terminable upon request and do not obligate us to produce any
minimum quantities of products within specified periods.
Historically our business strategy has entailed purchasing
concentrates, flavors, dietary ingredients, cans, bottles, caps, labels, and other components and ingredients for our beverage products
from our suppliers, which are delivered to our manufacturing operations and various third-party bottlers and co-packers. In some cases,
certain common supplies may be purchased by our various third-party bottlers and co-packers. Depending on the product, the third-party
bottlers or packers add other ingredients for the manufacture and packaging of the finished products into our approved containers in accordance
with our formulas.
Distribution
For our beverage-alcohol products, we operated within
what is referred to as a “Three Tier Distribution System” where manufacturers are not permitted to sell directly to retailers,
but instead contract for local and regional distribution with independent distributors. These distributors typically have geographic rights
to distribute major beverage brands and call on every store in a given area such as major cities or regions. Our President and CMO has
extensive experience working within this channel and believes that we may be successful in building a strong network of these distributors.
In addition to working with these independent distributors,
we also previously established distribution arrangements with national retail accounts.
Employees
We have one full-time employee our President who has
extensive experience in the beverage business, one part-time employee, our Chief Financial Officer and a part-time accounting consultant.
All of our employees and our consultant work remotely.
Listing on the NYSE American
Our Common Stock is listed on the NYSE American exchange
under the ticker symbol “SBEV”.
Corporate Information
We are a Nevada corporation. Our website address is www.splashbeveragegroup.com.
Our website is not incorporated into this Report.
4
Available Information
We file annual, quarterly, and current reports, proxy
statements and other information with the U.S. Securities Exchange Commission (the “SEC”). These filings are available to
the public through the SEC’s website at http://www.sec.gov. All statements made in any of our securities filings, including all
forward-looking statements or information, are made as of the date of the document in which the statement is included unless otherwise
specified, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do
so by law.